2ACO
| Xray structure of Blc dimer in complex with vaccenic acid | Descriptor: | Outer membrane lipoprotein blc, VACCENIC ACID | Authors: | Campanacci, V, Bishop, R.E, Reese, L, Blangy, S, Tegoni, M, Cambillau, C. | Deposit date: | 2005-07-19 | Release date: | 2006-08-01 | Last modified: | 2023-08-23 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | The membrane bound bacterial lipocalin Blc is a functional dimer with binding preference for lysophospholipids. Febs Lett., 580, 2006
|
|
1THQ
| Crystal Structure of Outer Membrane Enzyme PagP | Descriptor: | (4S)-2-METHYL-2,4-PENTANEDIOL, ACETATE ION, CrcA protein, ... | Authors: | Ahn, V.E, Lo, E.I, Engel, C.K, Chen, L, Hwang, P.M, Kay, L.E, Bishop, R.E, Prive, G.G. | Deposit date: | 2004-06-01 | Release date: | 2004-08-10 | Last modified: | 2024-02-14 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | A hydrocarbon ruler measures palmitate in the enzymatic acylation of endotoxin. Embo J., 23, 2004
|
|
1MM5
| Solution NMR structure of the outer membrane enzyme PagP in OG micelles | Descriptor: | CrcA protein | Authors: | Hwang, P.M, Choy, W.-Y, Lo, E.I, Chen, L, Forman-Kay, J.D, Raetz, C.R.H, Prive, G.G, Bishop, R.E, Kay, L.E. | Deposit date: | 2002-09-03 | Release date: | 2002-09-13 | Last modified: | 2024-05-22 | Method: | SOLUTION NMR | Cite: | Solution Structure and Dynamics of the Outer Membrane Enzyme PagP by NMR Proc.Natl.Acad.Sci.USA, 99, 2002
|
|
1MM4
| Solution NMR structure of the outer membrane enzyme PagP in DPC micelles | Descriptor: | CrcA protein | Authors: | Hwang, P.M, Choy, W.-Y, Lo, E.I, Chen, L, Forman-Kay, J.D, Raetz, C.R.H, Prive, G.G, Bishop, R.E, Kay, L.E. | Deposit date: | 2002-09-03 | Release date: | 2002-09-13 | Last modified: | 2024-05-22 | Method: | SOLUTION NMR | Cite: | Solution Structure and Dynamics of the Outer Membrane Enzyme PagP by NMR Proc.Natl.Acad.Sci.USA, 99, 2002
|
|
6DCG
| Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology | Descriptor: | (3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)-N-(3-{6-[(propan-2-yl)oxy]pyridin-3-yl}-1H-indazol-5-yl)pyrrolidine-3-carboxamide, Mitogen-activated protein kinase 1, SULFATE ION | Authors: | Boga, S.B, Deng, Y, Zhu, L, Nan, Y, Cooper, A, Shipps Jr, G.W, Doll, R, Shih, N, Zhu, H, Sun, R, Wang, T, Paliwal, S, Tsui, H, Gao, X, Yao, X, Desai, J, Wang, J, Alhassan, A.B, Kelly, J, Patel, M, Muppalla, K, Gudipati, S, Zhang, L, Buevich, A, Hesk, D, Carr, D, Dayananth, P, Mei, H, Cox, K, Sherborne, B, Hruza, A.W, Xiao, L, Jin, W, Long, B, Liu, G, Taylor, S.A, Kirschmeier, P, Windsor, W.T, Bishop, R, Samatar, A.A. | Deposit date: | 2018-05-06 | Release date: | 2018-08-08 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.45 Å) | Cite: | MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology. ACS Med Chem Lett, 9, 2018
|
|